The intersection of strong fundamental growth and an actionable technical setup is where many of the best risk-reward opportunities sit. The idea is straightforward: you want companies whose business metrics are clearly accelerating, but you also want to buy them at a point in the chart where the price is coiling before a potential breakout, rather than chasing a stock that has already run away. This dual-filter approach helps avoid the trap of buying great companies at terrible prices, and it prevents you from being lured into a stock that looks good on a chart but has no underlying business substance.
A company that currently checks both boxes is Vericel Corp (NASDAQ:VCEL). This Cambridge-based biotech firm focuses on patient-specific cellular therapies, primarily for cartilage repair (MACI), severe burn treatment (Epicel), and eschar removal in burn patients (NexoBrid). It occupies a specialized niche where regulatory barriers and manufacturing difficulty create meaningful competitive insulation.
Strong Growth in a Niche Market
The core requirement for any strong growth stock is that the business is actually expanding, not just the share price. On that front, Vericel presents a convincing picture. The fundamental analysis report awards the company an overall rating of 7 out of 10, with growth scoring an 8 out of 10. The numbers behind that score are striking.
- Earnings Per Share (EPS) growth has been explosive, surging 1300% over the past year. On a multi-year average, EPS has grown at a compound rate of roughly 44% annually.
- Revenue growth is also steady and consistent, with the last year showing a 22.45% increase, backed by a five-year average of 17.34% per year.
- Looking forward, analysts expect EPS to continue growing at nearly 50% annually, with revenue growth stabilizing around 19%.
This combination of high absolute growth and stable forward visibility is exactly what the strategy targets. You are betting on a company that is not just having a good quarter, but appears to be on a sustained compounding trajectory. The profitability rating of 8 out of 10 supports this, with the company showing margins that rank it in the top 10-15% of the Biotechnology industry, including a gross margin of 74.84% and a profit margin of 7.35% that has been improving. This indicates their cell therapies are being scaled profitably.
A Technical Setup Ready for Action
Strong fundamentals explain what to buy, but the technical setup tells you when to consider an entry. This is where the technical analysis report adds genuine value, awarding VCEL a stellar technical rating of 9 out of 10 and a setup rating of 7 out of 10.
The chart is currently exhibiting a classic bull flag pattern. After a strong upward move, the price has pulled back and is now consolidating in a tight range. This is often interpreted as a pause before the next leg higher. Several other signals reinforce this:
- Trends are positive: Both the short-term and long-term trends are positive, with the stock trading well above its rising 50-day ($39.42) and 200-day ($36.79) moving averages.
- Strong relative performance: The stock is outperforming 84% of all stocks on a yearly basis and has gained over 28% in the last three months.
- Clear support and resistance: A defined resistance zone sits between $46.99 and $47.01. A decisive move above this level could trigger the breakout. A solid support zone is located just below the current price between $45.49 and $45.87, providing a logical level for an initial stop-loss.
This combination of a business in clear growth mode and a chart that is consolidating into a potential breakout is the textbook definition of the strategy in action. It moves you beyond simply identifying a good company and into the area of identifying a favorable entry point.
When Criteria Converge
What makes a stock like VCEL interesting for this strategy is not just that it scores well on individual metrics, but how those metrics reinforce each other. The high growth and profitability ratings provide the conviction needed to hold a position through minor volatility. The strong technical setup with a clear bull flag provides the tactical trigger. The health rating of 7 out of 10 adds a layer of resilience, showing that the growth is not being funded by excessive debt—VCEL carries virtually no net debt, with a debt-to-equity ratio of 0.00.
For investors looking for more candidates that fit this specific profile—companies with strong growth and a technical breakout pattern in place—you can run the full screen on ChartMill. The same methodology used to identify this opportunity can be applied across the market to find other stocks meeting these criteria.
Click here to view more results from the Strong Growth Stock Technical Setups Screen.
Conclusion
Vericel Corp presents a strong case for the "strong growth with a technical setup" strategy. Its fundamental profile shows a company with accelerating earnings, consistent revenue growth, and expanding margins. Its technical profile shows a stock in a strong uptrend that is currently consolidating in a bull flag pattern, suggesting a potential breakout. This convergence of strong business performance and a favorable chart structure is the precise reason the strategy is worth paying attention to.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making any trading decisions.
Read full article here »
View the Zacks #1 Rank List
Vericel Corp (NASDAQ:VCEL): Strong Growth Stock With a Bull Flag Breakout Setup
The intersection of strong fundamental growth and an actionable technical setup is where many of the best risk-reward opportunities sit. The idea is straightforward: you want companies whose business metrics are clearly accelerating, but you also want to buy them at a point in the chart where the price is coiling before a potential breakout, rather than chasing a stock that has already run away. This dual-filter approach helps avoid the trap of buying great companies at terrible prices, and it prevents you from being lured into a stock that looks good on a chart but has no underlying business substance.
A company that currently checks both boxes is Vericel Corp (NASDAQ:VCEL). This Cambridge-based biotech firm focuses on patient-specific cellular therapies, primarily for cartilage repair (MACI), severe burn treatment (Epicel), and eschar removal in burn patients (NexoBrid). It occupies a specialized niche where regulatory barriers and manufacturing difficulty create meaningful competitive insulation.
Strong Growth in a Niche Market
The core requirement for any strong growth stock is that the business is actually expanding, not just the share price. On that front, Vericel presents a convincing picture. The fundamental analysis report awards the company an overall rating of 7 out of 10, with growth scoring an 8 out of 10. The numbers behind that score are striking.
This combination of high absolute growth and stable forward visibility is exactly what the strategy targets. You are betting on a company that is not just having a good quarter, but appears to be on a sustained compounding trajectory. The profitability rating of 8 out of 10 supports this, with the company showing margins that rank it in the top 10-15% of the Biotechnology industry, including a gross margin of 74.84% and a profit margin of 7.35% that has been improving. This indicates their cell therapies are being scaled profitably.
A Technical Setup Ready for Action
Strong fundamentals explain what to buy, but the technical setup tells you when to consider an entry. This is where the technical analysis report adds genuine value, awarding VCEL a stellar technical rating of 9 out of 10 and a setup rating of 7 out of 10.
The chart is currently exhibiting a classic bull flag pattern. After a strong upward move, the price has pulled back and is now consolidating in a tight range. This is often interpreted as a pause before the next leg higher. Several other signals reinforce this:
This combination of a business in clear growth mode and a chart that is consolidating into a potential breakout is the textbook definition of the strategy in action. It moves you beyond simply identifying a good company and into the area of identifying a favorable entry point.
When Criteria Converge
What makes a stock like VCEL interesting for this strategy is not just that it scores well on individual metrics, but how those metrics reinforce each other. The high growth and profitability ratings provide the conviction needed to hold a position through minor volatility. The strong technical setup with a clear bull flag provides the tactical trigger. The health rating of 7 out of 10 adds a layer of resilience, showing that the growth is not being funded by excessive debt—VCEL carries virtually no net debt, with a debt-to-equity ratio of 0.00.
For investors looking for more candidates that fit this specific profile—companies with strong growth and a technical breakout pattern in place—you can run the full screen on ChartMill. The same methodology used to identify this opportunity can be applied across the market to find other stocks meeting these criteria.
Click here to view more results from the Strong Growth Stock Technical Setups Screen.
Conclusion
Vericel Corp presents a strong case for the "strong growth with a technical setup" strategy. Its fundamental profile shows a company with accelerating earnings, consistent revenue growth, and expanding margins. Its technical profile shows a stock in a strong uptrend that is currently consolidating in a bull flag pattern, suggesting a potential breakout. This convergence of strong business performance and a favorable chart structure is the precise reason the strategy is worth paying attention to.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making any trading decisions.
Read full article here »